Compare TG Therapeutics Inc (TGTX) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs United Parcel Service Inc — how do they compare? TG Therapeutics Inc trades at $49.53 (market cap $7.64B), while United Parcel Service Inc trades at $103.9 (market cap $88.85B). The key difference: United Parcel Service Inc is far larger — about 11.6× TG Therapeutics Inc's market cap, and United Parcel Service Inc pays a 6.28% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | UPS | |
|---|---|---|
Market Cap | $7.64B | $88.85B |
Sector | Health | Industrials |
52-Week High | $59.06 | $120.00 |
52-Week Low | $26.94 | $82.58 |
Enterprise Value | $7.84B | $112.87B |
Volume | — | 2,288,643 |
Dividend Yield | — | 6.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
UPS stock trades at $103.72, down 0.95% on the day, with a bearish technical signal from moving averages. Recent quarterly earnings have consistently beaten estimates, with Q2 2026 EPS of $1.76 versus $1.65 expected. Revenue for 2025 was $88.66 billion, though net income margin has trended down to 5.08% in 2026. The company maintains a solid dividend of $1.64 per share and is focusing on automation and healthcare logistics to drive growth.
The outlook is mixed: analyst consensus is a Buy with a $117.90 price target, but technicals suggest near-term pressure. Key opportunities include strategic shifts away from low-margin business and digital tool enhancements for SMBs. Risks involve cost pressures, competitive threats, and dividend sustainability concerns as it consumed nearly all free cash flow in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
